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Retinal degeneration due to genetic, diabetic and age-related disease is the most common cause of
blindness in the developed world. Blindness occurs through the loss of the light-sensing photoreceptors;
to restore vision, it would be necessary to introduce alternative photosensitive components into the eye.
The recent development of an electronic prosthesis placed beneath the severely diseased retina has shown
that subretinal stimulation may restore some visual function in blind patients. This proves that residual
retinal circuits can be reawakened after photoreceptor loss and deﬁnes a goal for stem-cell-based therapy
to replace photoreceptors. Advances in reprogramming adult cells have shown how it may be possible to
generate autologous stem cells for transplantation without the need for an embryo donor. The recent suc-
cess in culturing a whole optic cup in vitro has shown how large numbers of photoreceptors might be
generated from embryonic stem cells. Taken together, these threads of discovery provide the basis for
optimism for the development of a stem-cell-based strategy for the treatment of retinal blindness.
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1. INTRODUCTION
A recent publication in this journal described how an
electronic device implanted under the human retina
could restore vision to a blind eye [1]. One patient was
able to read large print despite years of visual impairment
prior to implantation. This ﬁnding and others conﬁrm
that a retina that has lost all light-sensitive cells—the
photoreceptors—might regain function if residual neur-
ons are stimulated by new light-sensing components,
despite neuronal and glial reorganization [2–4]. The dis-
covery that a device implanted under the retina can
achieve vision restoration is signiﬁcant because the stimu-
lus is placed where the original light-sensitive cells would
have been located, taking advantage of downstream pro-
cessing that occurs in other retinal neurons before
signals reach the visual cortex. This ﬁnding supports the
development of stem cell treatments to replace photo-
receptors as such treatments would be delivered to this
same anatomical location.
In cell replacement therapy for most central nervous
system (CNS) diseases, replacement neurons would
need to develop afferent and efferent connections with
the host. In some cases, the replacement neurons would
need to navigate across long distances, and it is unlikely
that the necessary axon guidance cues would persist in
the adult brain [5]. Blindness in retinal degenerations is
caused by death of the ﬁrst neuron in its pathway: the
photoreceptor. Photoreceptors, stimulated by photons,
are not dependent on afferent synapses. Replacement
cells (ﬁgure 1a) would need to make only one efferent con-
nection with an adjacent second-order neuron in the host
inner retina with no need for navigation, to re-establish
the visual circuit. It is therefore arguable that the
photoreceptor is among the most readily transplantable
neurons in the CNS, and is an excellent candidate for clini-
cal trials exploring regenerative neural stem cell therapies.
2. THE CLINICAL NEED
Age-related, diabetic and genetic retinal degenerations
account for over 50 per cent of blind patients in the devel-
oped world [7]. Retinitis pigmentosa (RP) is the leading
cause of inherited retinal blindness in younger patients,
with a prevalence of approximately 1 :4000 [8]. Retinitis
pigmentosa is a term encompassing a group of disorders,
caused by mutations in over 150 genes discovered to date
[9], that cause photoreceptor loss which typically pro-
gresses to involve the central retina at which point all
sight is lost (ﬁgure 1b).
Age-related macular degeneration (AMD) is a
common disease with genetic and environmental risk fac-
tors [10,11]. AMD affects 14 million elderly people in the
developed world [11,12]. Ninety per cent of patients
suffer from the form termed dry AMD, which is charac-
terized by primary degeneration of retinal pigment
epithelium (RPE) cells leading to secondary photo-
receptor loss [13] and is currently untreatable (ﬁgure 1c).
Oneotherretinopathyhasattractedattentionforstemcell
therapy. Stargardt disease is the most common inherited
juvenile macular degeneration [14]. Symptoms begin typi-
cally between the ages of 6 and 12, with a variably * Author for correspondence (robert.maclaren@eye.ox.ac.uk).
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Technology (ACT), a US-based company, announced that
they had gained regulatory approval to use embryonic stem
(ES) cells to replace RPE in a phase I/II clinical trial
involving patients with Stargardt disease (http://www.advan
cedcell.com/news-and-media/press-releases/advanced-cell-
technology-receives-fda-clearance-for-the-ﬁrst-clinical-
trial-using-embryonic-stem-cel/, accessed 5 April 2011).
In this proposed therapy, treatment will target RPE
replacement to restore function and/or prevent loss of
photoreceptors. However, once photoreceptors are lost in
advanced degeneration, treatment must involve reintro-
duction of light-sensitive cells. The challenge for retinal
stem cell therapy lies in the generation of numerous photo-
receptorcells, at the ideal developmental stage to integrate,
free of malignant potential and immunogenicity. Although
close, this has not yet been achieved to a level sufﬁcient to
consider clinical trial approval; the on-going work with
RPE will provide valuable safety data to support future
trials using stem cell approaches to replace photoreceptors.
3. THE RETINA: AN IDEAL TESTING GROUND FOR
NEURAL REGENERATION
The human retina contains rod photoreceptors for vision in
low light and cone photoreceptors for colour and high-
acuity vision in bright light. Photoreceptors depend on
RPEformetabolicactivity(ﬁgure2).Also,conesaredepen-
dent for survival on the rods through a number of putative
mechanisms, including paracrine support [15]; the loss of
one class of cell therefore leads to the secondary loss of
others. Hence, cell replacement strategies in RP might
aim to reintroduce rods in order to rescue cones from
degeneration,oralternativelytorestorenightvisiondirectly.
Retinal cell therapy is likely to be delivered using small-
gauge vitrectomy, a procedure now routinely performed on
an outpatient basis with low morbidity. The range of assess-
ments for retinal structure and function can provide the
safety and efﬁcacy data required in clinical trials. Confocal
scanning laser ophthalmoscopy reveals retinal structure to
ar e s o l u t i o no f7mm[ 16] and may be employed to visualize
cell grafts. Whereas grafts in other organs may be difﬁcult to
visualize, they mayeasily be monitored in the retina through
the clear cornea and lens. As uncontrolled proliferation is a
concern foranystem cell treatment, graft site visualization is
a distinct advantage in terms of safety. Also, cells would be
transplanted into the subretinal space, a discrete compart-
ment that would limit the systemic spread of immature
cells. Laser photocoagulation—used routinely in advanced
diabetic retinopathy—could be used if necessary to destroy
transplanted cells non-invasively. A range of tests including
visual electrophysiology, microperimetry, contrast sensitivity
and mobility testing (among others) are available to assess
visual function and treatment efﬁcacy even when only a
minimal degree of function remains, as will be the case in
patients requiring therapy. Furthermore, the fellow eye pro-
vides a control as retinal degenerations are frequently
bilateral and symmetrical.
4. CHALLENGES IN RETINAL REPLACEMENT
The ﬁrst report of mammalian retinal transplantation by
Katharine Tansley [17] initiated decades of interest in
the use of immature tissue for retinal replacement
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Figure 1. Outerretinaldegenerationsmayinfuturebeamenable
to cell replacement. (a) Successful integration of a donor photo-
receptor, expressing green ﬂuorescent protein (GFP; green) and
labelled with bromodeoxyuridine (BrdU), into a host outer
nuclear layer (ONL). INL, inner nuclear layer (reproduced
with kind permission from MacLaren & Pearson [6], q 2007
Nature Publishing). (b) Retinitis pigmentosa (here, Thr17Met
rhodopsinmutation)startsintheretinalperiphery,withpigmen-
tary changes (arrowheads) owing to degeneration of the outer
retina. The disease commonly proceeds to threaten the foveal
centre and will then affect central vision. (c)D r ya g e - r e l a t e d
macular degeneration is characterized by white deposits called
drusen. Here a large, central patch of retinal pigment epithelium
and outer retinal atrophy is seen (margins demarcated with
arrowheads), and would be consistent with markedly reduced
visual acuity.
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occur in embryonic and foetal retinal cells upon matu-
ration [23,24], and provide the basis to be hopeful for
the development of functional photoreceptors from
immature cells.
For successful integration, the grafted photoreceptors
should assume the correct orientation, with an inner
synapse and an outer photoreceptive segment positioned
against host inner retina and RPE, respectively. To this
end, different methods of donor cell preparation have
been proposed. Whole retinal sheets derived from
embryonic or neonatal rodents can survive and differen-
tiate after subretinal transplantation [25–27]. A recent
study employed attenuated pseudorabies virus to label
graft neurons and showed that full-thickness retinal
sheets, while not integrating directly, could connect with
host neurons [28]. Similar observations have been made
with partial-thickness sheets [29,30]. A lack of integration
is likely to be more of a problem when using a single-cell
suspension as orientation will be signiﬁcantly disrupted,
and, furthermore, there is a tendency for rosette for-
mation [31,32]. These cells would be unable to
generate visual responses if aggregations directed light-
induced currents away from host retina (ﬁgure 3a,b).
The relative ease of surgical delivery, however, has made
the use of single-cell suspensions appealing and it has
been widely investigated [32,34,35], with evidence that
some cells integrate into host retina and make synaptic
connections [36]. Currently, the percentage of cells able
to integrate and make connections is low (approximately
0.1 per cent) [37]. Given that millions of photoreceptors
will probably be needed to restore meaningful vision, the
challenge for the cell suspension approach will be to gen-
erate sufﬁcient numbers of cells and in parallel to improve
integration efﬁciency.
Positioned in the subretinal space, the immature cell
must develop an inner process specialized for synaptic
transmission to second-order neurons. Evidence of
neural integration following transplantation has been
presented [30,38–43]; however, as typiﬁed by these
studies, accurate discrimination of donor and host is a
challenge because graft–host synapses are difﬁcult to
distinguish from intra-graft synapses (ﬁgure 3c,d ).
Notably, synapses may not be necessary as residual reti-
nal cells may, in theory, be stimulated by a proximate
potential change, as exempliﬁed by the retinal implant
device.
Transplantation into the retina may be hampered by
gliosis (ﬁgure 3e,f ), although this may be less marked
than other CNS sites [44–46]. Disruption of glial barriers
may result in better integration [37,47,48]. Clinically, it is
recognized that intra-retinal RPE migration is a feature of
RP, which may imply that gliosis could still allow for cell
integration to some extent.
A critical translational question is whether trans-
planted stem or precursor cells will improve function in
a degenerate host. Hosts that still have at least some
degree of outer retinal architecture have shown functional
improvement following photoreceptor replacement
[36,49–53]. However, it is not known whether vision
can be restored in a severely degenerate retina with pro-
longed photoreceptor loss. It will be critical to address
this in order to apply these treatments in patients with
severe blindness.
Clinical trials have shown that the human foetal retina
can be transplanted into the subretinal space without
signiﬁcant surgical adverse reactions [54] or immune rejec-
tion [55]. However, another report presented angiographic
evidence of inﬂammation after a similar transplant [56],
with no effect on vision. Nevertheless, these pioneering
studies show that transplantation of immature tissue into
the severely degenerated retina in humans is a safe pro-
cedure, so the question of whether such transplants can
restore sight may soon be answered.
(a)( b)
Figure 2. (a) Normal retina. Photoreceptor cells are the light sensors in the visual system. In the laminations of the normal
human retina shown here, photoreceptors lie in the outer retina, optimally oriented to detect the incidence of photons. The
photoreceptors have a light-sensitive outer end that is apposed to retinal pigment epithelium (RPE), and an inner end special-
ized for synaptic transmission that is connected to second-order neurons in the inner retina. When stimulated, photoreceptors
generate impulses that are processed by inner retinal cells and then conveyed to the brain via the optic nerve. Visual sensation is
produced when impulses reach the visual cortex in the occipital lobe. (b) Severe retinal degeneration. In the diagram above, all
photoreceptors have been lost and the retina is unable to sense incident light. There are no signals conveyed to the inner retina
and brain, and the patient is therefore blind. Retinal sensitivity may, in principle, be restored by placing new light-sensing com-
ponents, such as stem/precursor cells or an electronic prosthetic device, between host inner retina and host RPE (location
marked by asterisks), where photoreceptors would normally be located. In this way, inner retinal processing is used to optimize
the signals generated from the new light sensors before these are transmitted to the cortex. (Reproduced with kind permission
from MacLaren & Pearson [6], q Nature Publishing.)
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ES cells, derived from the inner cell mass of blastocyst-
stage embryos [57–59] ,a r ea b l et om a i n t a i na nu n d i f f e r e n -
tiated state or can be directed to mature along lineages
deriving from all three germ layers—ectoderm, endoderm
and mesoderm. Photoreceptor features were found in sub-
retinal human ES cell grafts, but not in locations elsewhere
in the eye, indicating that the subretinal niche may be criti-
cal to support differentiation of ES cells towards a
photoreceptor fate [60]. Retinal fate has also been induced
in mouse, monkey and human ES cells by using growth fac-
tors, retinal co-culture and genetic modiﬁcation [61,62].
When directed to become retinal precursors similar to the
human foetal stage, human ES cells were found to integrate
into an explant model of Leber congenital amaurosis [63]
and restore some function in vivo [64]. These data strongly
support the use of precursor cells for photoreceptor repla-
cement. It may be that for effective integration, stem cells
need to be differentiated some way along the photoreceptor
lineage before transplantation; recent evidence has
suggested that even mature neurons may integrate [65].
Very recently, it was shown that three-dimensional culture
of mouse ES cell aggregates led to autonomous optic cup
formation in vitro with features of retinal stratiﬁcation
[66]. A similar system might be applicable to expand and
differentiate a single ES cell into potentially thousands of
photoreceptor precursors (or some other photoreceptor
developmental stage) for optimal integration.
Despite the relative ocular immune privilege, ES cells
are immunogenic as they originate from another human
foetus, which also raises ethical questions about how to
source these cells. The discovery that reprogramming
DNA-binding proteins may induce stem cells from adult
cells represents a milestone in the search for a renewable
source of cells [67–69]. These ‘induced pluripotent’ stem
(iPS) cells, being autologous, may obviate the need for
chronic immune suppression.
iPS clones could be derived from patients and be used
for treatment—a process that may involve ex vivo correc-
tion of the gene defect before reintroduction into the host.
Recent progress has been made as iPS cells derived from
amyotrophic lateral sclerosis patients have been differen-
tiated into motor neurons—the cell type that requires
replacement in this condition [70]. In a similar vein,
human iPS cells have been cloned from Parkinson’s dis-
ease patients [71] and iPS cell-derived dopamine
neurons have improved function in a Parkinson’s disease
model [72]. However, iPS clones vary in pluripotency
and differentiate less efﬁciently than ES cells, which
show robust neuronal differentiation [73]. Interestingly,
(a) (b)
(c) (d)
(e) (f)
Figure 3. Challenges in cell-based retinal therapy. (a,b) Rosette formation hampers integration of transplanted precursor cells.
Here, retinal cells from nrl.gfp
þ/þ mice (see [33]) that express green ﬂuorescent protein (GFP; green) in post-mitotic rod pre-
cursors were dissociated before subretinal transplantation. Rosettes (asterisks) formed after transplantation, and there was poor
donor–host integration. Scale bar, 50mm. (c,d) Accurate labelling of host cells is important to interpret morphology. GFP-
positive donor cells extend processes from the cell bodies. Whereas some processes (arrows) appear to extend within the
graft, others (arrowheads) appear to point towards host tissue. However, without a histological marker for host cells, synaptic
connections of donor and host are difﬁcult to demonstrate. Scale bar, 10mm. (e,f ) Integration may be prevented by gliosis in
degenerated hosts. Here, GFP-positive cells do not extend processes into the host retina, and a sharp demarcation is seen
(arrowheads) between the donor cell mass and host retina, presumably owing to advanced gliosis. Scale bar, 25mm. (b,d,f )T h e
merged GFP and transmitted light channels. Nuclei are counterstained with Hoechst-33342 (blue).
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iPS cell production. Integrating vectors such as lenti-
viruses (whereby genes are inserted into the target cell
genome), in addition to affecting pluripotency, confer a
greater potential risk of teratogenicity than non-integrat-
ing vectors (whereby the gene is expressed while
remaining separate from the host genome). By avoiding
the use of genes and vectors associated with uncontrolled
proliferation [74,75], the risk of tumour formation is
reduced. Ideally, iPS cells derived from every patient
will need to be screened for potentially cancerous cells,
as even a 0.01 per cent risk of malignancy induced by
therapy may be unacceptable for patients and doctors.
The situation is somewhat different with ES cells, which
are not derived from individual patients—potentially, a
few well-characterized, puriﬁed and approved cell lines
may be used widely. Overall, the regulatory environment
will be complex, given the range of pluripotency, differen-
tiation capacity, teratogenicity and immunogenicity of
different iPS cell clones and ES cell lines. It is likely
that a range of pre-treatment protocols, potentially sub-
ject to differing regulatory requirements, will be
developed in future, tailored to speciﬁc clinical situations.
iPS cells have differentiated in vitro into retinal cell
phenotypes, recapitulating events in normal development
[76,77]. Functional human photoreceptor-like cells have
been observed following differentiation of human iPS
cells [78,79]. In the case of retinal degenerations, iPS
cells from patients might be used for replacement, with
correction of the RP gene defect and the cells then
directed to assume a retinal precursor fate before trans-
plantation (ﬁgure 4). For therapy, abundant autologous
cells should be generated at a stage with maximal integra-
tive capacity. For regulatory purposes, it would be optimal
to use protocols that do not rely upon materials of
bacterial or animal origin; low-molecular-weight com-
pounds have been shown to induce retinal progenitors,
RPE and photoreceptors from ES and iPS cells [80].
6. RETINAL PIGMENT EPITHELIUM CELL
TRANSPLANTATION
In AMD, the primary cell to be lost is the RPE cell, lead-
ing to a secondary loss of photoreceptors. Hence, it has
been asked if RPE replacement may delay or prevent
blindness in AMD. Photoreceptor rescue has been
reported after transplantation of foetal RPE cells in ani-
mals, even in advanced disease [81]. This approach has
not yet, however, shown convincing effect in AMD
patients [82,83]. This is in contrast to autologous grafts,
which included Bruch’s membrane, an underlying plat-
form that maintains RPE polarity and homeostasis
[84,85]. Hence, the challenge in using stem cells for
RPE replacement will probably be to ﬁnd a means of
integrating differentiated RPE cells with a basement
membrane—recreating cell adhesion junctions to
Bruch’s membrane or an alternative substrate, rather
than creating synapses with host neurons.
In searching for renewable RPE cells, RPE-like cells
have been derived from non-human primate and human
ES cells [86–88]. Human ES-cell-derived RPE has been
shown to improve retinal function in a rat model of
AMD [89–91], and iPS-cell-derived RPE was found to
have protective effects in dystrophic rats [92]. Human
ES-cell-derived RPE cells have been studied for prolonged
periods and found to sustain function without evidence of
teratoma formation [93], paving the way to clinical appli-
cation. The potential commencement of the recently
announced phase I/II trial using ES cells for RPE replace-
ment, discussed earlier, will encourage the development of
the ideal cell for translation into AMD patients.
7. CONCLUSION
The clinical need for therapies for retinal degeneration
has energized the search for renewable cells to replace
photoreceptors in patients. It is known that the diseased
human retina may recover function if appropriately stimu-
lated by an electrical current, and separately it has been
demonstrated that rod photoreceptor precursor cells
may mature, differentiate and function in the host
environment after transplantation. Moreover, large num-
bers of cells may potentially be generated from a single
stem cell in an optic cup culture model. The convergence
of these discoveries sets the foundation in the near future
for a clinically applicable stem cell strategy to restore
vision in patients with retinal degenerations.
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Figure 4. 1. A suitable cell is obtained from the patient with
retinal disease. An easily accessible source of cells is chosen
so as to minimize surgical trauma. The example of a skin ﬁbro-
blast is depicted here. 2. The capacity for self-renewal—absent
in almost all adult cells—is restored in vitro through genetic
reprogramming or other means, so that this cell may be
expanded in numbers later on. In theory, only one repro-
grammed cell is required to repopulate any diseased tissue.
Reprogramming methods should be chosen that minimize the
risk of mutagenesis and uncontrolled proliferation. 3. The gen-
etic mutation that caused blindness in this patient could, in
principle, be corrected at this stage by ex vivo gene therapy.
Other modiﬁcations may also be added to enhance cell survival
and integration in the host. 4. This genetically corrected auto-
logous cell is expanded in vitro to produce the large number of
cells required for a therapeutic effect. Preferably, products
derived from animals or bacteria are not used in the cell culture
protocol. 5. The cells are made to develop up to a stage known
to lead to optimal integration and function upon transplan-
tation. The resultant colony must ideally be free of malignant
potential and immunogenicity. 6. The cells are delivered to
the subretinal space using well-established surgical techniques
with low morbidity, such as small-gauge vitrectomy.
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National University Health System, Singapore.
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